Fate Therapeutics Inc (FATE)

[jondoeuk]

Speaking of GD2 https://www.nature.com/articles/s41591-023-02363-y

Also, for NKT's; Co-Expression of the IL15-IL15a Complex with a 41BB-Based Chimeric Antigen Receptor Promotes Superior Antitumor Activity in NKT Cells https://annualmeeting.asgct.org/abstracts/abstract-details?abstractId=14399

IL-12 Reprograms CAR-Expressing NKT Cells to Long-Lived Th1-Polarized Antitumor Effector Cells https://annualmeeting.asgct.org/abstracts/abstract-details?abstractId=14440

Knocking-Down Expression of BTG1, a Key Driver of NKT Cell Exhaustion, Promotes Durable Tumor Control by CAR-NKTs in a Xenogeneic Neuroblastoma Model https://annualmeeting.asgct.org/abstracts/abstract-details?abstractId=14441

Harnessing CRISPR/Cas9 Mutagenesis Screening for Rational Design of Next-Generation CAR-NKT Therapy Against Neuroblastoma https://annualmeeting.asgct.org/abstracts/abstract-details?abstractId=14777

Tumor-Localized Administration of a-GalCer to Recruit Invariant Natural Killer T Cells and Enhance Their Antitumor Activity Against Solid Tumors https://annualmeeting.asgct.org/abstracts/abstract-details?abstractId=14780

High-Throughput Pooled Screen of CAR Library Identifies Essential Signaling Features of CAR-T Cells That Resist Immunosuppression https://annualmeeting.asgct.org/abstracts/abstract-details?abstractId=15069